In the main trial, inTandem 3 [90] the primary end point was a glycated hemoglobin level lower than 7.0% at week 24, without episodes of severe hypoglycemia or diabetic ketoacidosis, while secondary end points were the change from baseline to week 24 in glycated hemoglobin level and the possible reduction in daily bolus insulin dose, body weight and systolic blood pressure. The gene discussed is INS; the disease is Hypoglycemia.